{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:16Z","timestamp":1772165656340,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"This work was supported by King\u2019s Sierra Leone Partnership through a European and Developing Countries Clinical Trials Partnership grant for research capacity building","award":["EDCTP-CSA-Ebola-360"],"award-info":[{"award-number":["EDCTP-CSA-Ebola-360"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The global annual estimate for cryptococcal disease-related deaths exceeds 180,000, with three fourth occurring in sub-Saharan Africa. The World Health Organization (WHO) recommends cryptococcal antigen (CrAg) screening in all HIV patients with CD4 count &lt;\u2009100\/\u03bcl. As there is no previous published study on the burden and impact of cryptococcal disease in Sierra Leone, research is needed to inform public health policies. We aimed to establish the seroprevalence and mortality of cryptococcal disease in adults with advanced HIV attending an urban tertiary hospital in Sierra Leone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A prospective cohort study design was used to screen consecutive adult (18\u2009years or older) HIV patients at Connaught Hospital in Freetown, Sierra Leone with CD4 count below 100 cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      from January to April 2018. Participants received a blood CrAg lateral flow assay (IMMY, Oklahoma, USA). All participants with a positive serum CrAg had lumbar puncture and cerebrospinal fluid (CSF) CrAg assay, and those with cryptococcal diseases had fluconazole monotherapy with 8\u00a0weeks followed up. Data were entered into Excel and analysed in Stata version 13.0. Proportions, median and interquartile ranges were used to summarise the data. Fisher\u2019s exact test was used to compare categorical variables.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 170 patients, with median age of 36 (IQR 30\u201343) and median CD4 count of 45 cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      (IQR 23\u201363) were screened. At the time of enrolment, 54% were inpatients, 51% were newly diagnosed with HIV, and 56% were either ART-na\u00efve or newly initiated (\u2264 30\u2009days). Eight participants had a positive blood CrAg, giving a prevalence of 4.7% (95% CI: 2.4\u20139.2%). Of those with a positive CrAg, CSF CrAg was positive in five (62.5%). Five (62.5%) CrAg-positive participants died within the first month, while the remaining three were alive and established on ART at 8\u00a0weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A substantial prevalence of cryptococcal antigenaemia and poor outcome of cryptococcal disease were demonstrated in our study. The high mortality suggests a need for the HIV programme to formulate and implement policies on screening and pre-emptive fluconazole therapy for all adults with advanced HIV in Sierra Leone, and advocate for affordable access to effective antifungal therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-4862-x","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T10:04:54Z","timestamp":1581674694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7639-0004","authenticated-orcid":false,"given":"Sulaiman","family":"Lakoh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Rickman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momodu","family":"Sesay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sartie","family":"Kenneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamadu","family":"Baldeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darlinda F.","family":"Jiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf S.","family":"Tejan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Comfort","family":"Koroma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gibrilla F.","family":"Deen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenella","family":"Beynon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"issue":"8","key":"4862_CR1","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","volume":"17","author":"R Rajasingham","year":"2017","unstructured":"Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873\u201381.","journal-title":"Lancet Infect Dis"},{"key":"4862_CR2","unstructured":"WHO | Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. WHO. 2018; Available from: apps.who.int\/iris\/bitstream\/handle\/10665\/260399\/9789241550277-eng.pdf;jsessionid=30132897E0F565C43DF9DDFD1B0AFA3F?sequence=1. Accessed 13 Dec 2019."},{"issue":"4","key":"4862_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1086\/655143","volume":"51","author":"DB Meya","year":"2010","unstructured":"Meya DB, Manabe YC, Castelnuovo B, Cook BA, Ali M, Kambugu A, et al. Serum Cryptococcal antigen (CRAG) screening is a cost- effective method to prevent death in HIV- infected persons with CD4 <100\/uL starting HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51(4):448\u201355.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"4862_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0069288","volume":"8","author":"JN Jarvis","year":"2013","unstructured":"Jarvis JN, Harrison TS, Lawn SD, Meintjes G, Wood R, Cleary S. Cost effectiveness of Cryptococcal antigen screening as a strategy to prevent HIV-associated Cryptococcal meningitis in South Africa. PLoS One. 2013;8(7):1\u201310.","journal-title":"PLoS One"},{"issue":"3","key":"4862_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1615822","volume":"377","author":"J Hakim","year":"2017","unstructured":"Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, et al. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. N Engl J Med. 2017 Jul;377(3):233\u201345.","journal-title":"N Engl J Med"},{"issue":"12","key":"4862_CR6","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S1473-3099(11)70245-6","volume":"11","author":"R Parkes-Ratanshi","year":"2011","unstructured":"Parkes-Ratanshi R, Wakeham K, Levin J, Namusoke D, Whitworth J, Coutinho A, et al. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet Infect Dis. 2011;11(12):933\u201341.","journal-title":"Lancet Infect Dis"},{"key":"4862_CR7","unstructured":"Sierra Leone Demographic and Health Survey. 2013; Available from: www.statistics.sl\/images\/StatisticsSL\/Documents\/demographic_and_health_survey_2013_final-report.pdf. Accessed 10 Feb 2020."},{"key":"4862_CR8","unstructured":"WHO | WHO Global Health Workforce Statistics. WHO. 2018; Available from: www.who.int\/hrh\/statistics\/en\/. Accessed 12 Dec 2019."},{"issue":"11","key":"4862_CR9","doi-asserted-by":"publisher","first-page":"e110285","DOI":"10.1371\/journal.pone.0110285","volume":"9","author":"Katherine M. Gaskell","year":"2014","unstructured":"Gaskell KM, Rothe C, Gnanadurai R, Goodson P, Jassi C, Heyderman RS, et al. A Prospective Study of Mortality from Cryptococcal Meningitis following Treatment Induction with 1200mg Oral Fluconazole in Blantyre, Malawi. Filler SG, editor. PLoS One. 2014;9(11):e110285.","journal-title":"PLoS ONE"},{"issue":"3","key":"4862_CR10","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1097\/QAI.0000000000001183","volume":"74","author":"Tom H. Boyles","year":"2017","unstructured":"Boyles TH, Gatley E, Wasserman S, Meintjes G. Brief report. JAIDS J Acquir Immune Defic Syndr. 2017;74(3):e64\u20136.","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"issue":"2","key":"4862_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4103\/0976-3147.112729","volume":"4","author":"E Molyneux","year":"2013","unstructured":"Molyneux E. Where there is no laboratory, a urine patch test helps diagnose meningitis. J Neurosci Rural Pract. 2013 Apr;4(2):117\u20138.","journal-title":"J Neurosci Rural Pract"},{"key":"4862_CR12","unstructured":"World Health Organization. Sierra Leone Sierra Leone. Time. 2016, 2003;(January):\u20134."},{"key":"4862_CR13","unstructured":"Organization WH. Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children: December 2011. Geneva World Heal Organ. 2011;(December) Available from: http:\/\/apps.who.int\/iris\/handle\/10665\/44786."},{"key":"4862_CR14","doi-asserted-by":"crossref","unstructured":"Thomsen D, Hviid CJ, H\u00f8nge BL, Medina C, da Silva T\u00e9 D, Correira FG, et al. Increased mortality among HIV infected patients with cryptococcal antigenemia in Guinea-Bissau. Pan Afr Med J. 2018.","DOI":"10.11604\/pamj.2018.29.18.14099"},{"issue":"3","key":"4862_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.5001\/omj.2012.51","volume":"27","author":"F Osazuwa","year":"2012","unstructured":"Osazuwa F, Dirisu JO, Okuonghae PE, Ugbebor O. Screening for cryptococcal antigenemia in anti-retroviral na\u00efve AIDS patients in Benin City, Nigeria. Oman Med J. 2012;27(3):228\u201331.","journal-title":"Oman Med J"},{"issue":"2","key":"4862_CR16","doi-asserted-by":"publisher","first-page":"ofw055","DOI":"10.1093\/ofid\/ofw055","volume":"3","author":"RO Oladele","year":"2016","unstructured":"Oladele RO, Akanmu AS, Nwosu AO, Ogunsola FT, Richardson MD, Denning DW. Cryptococcal antigenemia in Nigerian patients with advanced human immunodeficiency virus: Influence of antiretroviral therapy adherence. Open Forum Infect Dis. 2016;3(2):ofw055.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"4862_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/QAI.0000000000001048","volume":"73","author":"EE Ezeanolue","year":"2016","unstructured":"Ezeanolue EE, Nwizu C, Greene GS, Amusu O, Chukwuka C, Ndembi N, et al. Brief report: geographical variation in prevalence of Cryptococcal Antigenemia among HIV-infected, treatment-naive patients in Nigeria: a multicenter cross-sectional study. J Acquir Immune Defic Syndr. 2016;73(1):117\u201321.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"4862_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-3156.2010.02683.x","volume":"16","author":"Y Mamoojee","year":"2011","unstructured":"Mamoojee Y, Shakoor S, Gorton RL, Sarfo S, Appiah LT, Norman B, et al. Short communication: low seroprevalence of cryptococcal antigenaemia in patients with advanced HIV infection enrolling in an antiretroviral programme in Ghana. Tropical Med Int Health. 2011;16(1):53\u20136.","journal-title":"Tropical Med Int Health"},{"issue":"2","key":"4862_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40475-015-0045-z","volume":"2","author":"D Meya","year":"2015","unstructured":"Meya D, Rajasingham R, Nalintya E, Tenforde M, Jarvis JN. Preventing Cryptococcosis\u2014shifting the paradigm in the era of highly active antiretroviral therapy. Curr Trop Med Reports. 2015;2(2):81\u20139.","journal-title":"Curr Trop Med Reports"},{"key":"4862_CR20","unstructured":"WHO. Rapid Advice: Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children. 2011. Available from: apps.who.int\/iris\/bitstream\/handle\/10665\/44786\/9789241502979_eng.pdf?sequence=1&isAllowed=y. Accessed 09 Feb 2020."},{"key":"4862_CR21","unstructured":"Loyse A, Burry J, Cohn J, Ford N, Chiller T, Ribeiro I, et al. Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. Lancet Infect Dis. 2018; Available from: www.dndi.org\/wp-content\/uploads\/2018\/10\/Loyse_Response_Evidence_Guidelines_CryptococcalMeningitis_LancetID_2018.pdf."},{"issue":"2","key":"4862_CR22","first-page":"16","volume":"50","author":"SA Vaidhya","year":"2015","unstructured":"Vaidhya SA. Combination versus Monotherapy for the treatment of HIV associated Cryptococcal meningitis. J Clin Diagnostic Res [Internet]. 2015;50(2):16\u20138 Available from: http:\/\/jcdr.net\/article_fulltext.asp?issn=0973-709x&year=2015&volume=9&issue=2&page=OC14&issn=0973-709x&id=5601.","journal-title":"J Clin Diagnostic Res [Internet]"},{"key":"4862_CR23","first-page":"2","volume-title":"HIV Treatment. Guidelines for managing advanced HIV disease and rapid initiation of ARV","author":"WHO","year":"2017","unstructured":"WHO. HIV Treatment. Guidelines for managing advanced HIV disease and rapid initiation of ARV; 2017. p. 2\u20135. Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/255885\/1\/WHO-HIV-2017.18-eng.pdf?ua=1"},{"issue":"9","key":"4862_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/ofid\/ofy208","volume":"5","author":"GA Yendewa","year":"2018","unstructured":"Yendewa GA, Poveda E, Lakoh S, Yendewa SA, Jiba DF, Salgado-Barreira A, et al. High prevalence of late-stage disease in newly diagnosed human immunodeficiency virus patients in Sierra Leone. Open Forum Infect Dis. 2018;5(9):7\u201310 Available from: https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofy208\/5078457.","journal-title":"Open Forum Infect Dis"},{"issue":"August","key":"4862_CR25","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1093\/cid\/ciy103","volume":"66","author":"J Ousley","year":"2018","unstructured":"Ousley J, Niyibizi AA, Wanjala S, Vandenbulcke A, Kirubi B, Omwoyo W, et al. High proportions of patients with advanced HIV are antiretroviral therapy experienced: hospitalization outcomes from 2 sub-Saharan African sites. Clin Infect Dis. 2018;66(August):S126\u201332.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4862-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-4862-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4862-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T14:34:31Z","timestamp":1613226871000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-4862-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4862"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-4862-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.11153\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11153\/v2","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]},"assertion":[{"value":"3 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the Sierra Leone Ethics and Scientific Review Committee (SLESRC) of the Ministry of Health and Sanitation, Government of Sierra Leone. When patients had the capacity, informed written consent was approved by SLESRC was sought and obtained for completion of a questionnaire and examination. For all patients, the consent form was explained verbally in their local languages. Where patients were illiterate, the study and the consent form content were explained to them verbally and they indicated consent through a witnessed fingerprint as approved by SLESRC. Patients who declined consent were still eligible for CrAg testing, but their data was not included in the analysis.Some eligible participants lacked capacity as a result of suspected neurological opportunistic infections. The inclusion of this group was important in understanding the prevalence of cryptococcal infection in the study population. It was not felt ethical to seek consent from a representative as this would have involved the disclosure of HIV status; less than a third of people living with HIV in Sierra Leone have disclosed their status to adult relatives and levels of stigma are extremely high [\n                      \n                      ]. As study procedures posed minimal risk to participants, anonymised data from patients who were unable to consent were therefore also included. Consent was sought retrospectively from participants who regained capacity. All participants were free to withdraw at any time, and data were stored confidentially and anonymously.All study protocols (including waiver of consent from the next-of-kin and the procedure of consent from the patients that lacked the capacity) were approved by the SLERSC.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}